New blood pressure drug shows promise for kidney disease in early trial

NCT ID NCT06428825

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called BAY3283142 in 75 people with mild to moderate high blood pressure. The drug is designed to relax blood vessels and is being developed for chronic kidney disease. Participants took different doses or a placebo for up to 10 weeks to check for safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAY3283142
What this could lead to: If this drug proves safe, it could lead to a new treatment option for chronic kidney disease by helping relax blood vessels.
What could go wrong: This is an early Phase 1 safety study with only 75 people, so it's too soon to know if the drug works or is safe long-term. Side effects like pain from blood draws are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIAL HYPERTENSION CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

CRS Clinical Research Services Berlin GmbH

Berlin, 13627, Germany
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit

Mannheim, Baden-Wurttemberg, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.